Subcutaneous · GLP-1 agonist
ZT006
2 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
2
Active
1
Recruiting
0
Completed
1
Sites
11
Countries
1
Endpoints
31
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
1
Phase 2
1
Trials by status
Active, not recruiting
1
Completed
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
15
Weight & body composition
9
Other (unclassified)
7
Most-measured metrics
Top 20 metrics across this asset's endpoints
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
2 of 2
| Asset / Population | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT07230132Efficacy and Safety of ZT006 in Overweight and Obese Participants | ZT006 Obesity / overweight | BMI ≥28 | Ph 2 | Active, not recruiting | 10 | Dec 2026 | — | |
| NCT07307638Dose-escalation and Food Effect Study of ZT006 in Healthy, Overweight and Obese Participants | ZT006 Healthy volunteers, Obesity / overweight | BMI 19-35 | Ph 1 | Completed | 1 | Jun 2025 | — |